{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:30:50Z","timestamp":1790238650229,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40266-019-00703-7","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T04:44:12Z","timestamp":1566449052000},"page":"969-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The FORTA (Fit fOR The Aged)-EPI (Epidemiological) Algorithm: Application of an Information Technology Tool for the Epidemiological Assessment of Drug Treatment in Older People"],"prefix":"10.1007","volume":"36","author":[{"given":"Andree","family":"Rabenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"703_CR1","unstructured":"Ortman JM, Velkoff VA. An aging nation: the older population in the United States. United States Census Bureau. \n                    https:\/\/www.census.gov\/prod\/2014pubs\/p25-1140.pdf\n                    \n                  . Accessed 03 May 2019."},{"key":"703_CR2","unstructured":"EUROSTAT Statistics explained. Population structure by major age groups. \n                    https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=File:Population_structure_by_major_age_groups,_EU-28,_2017-80_(%25_of_total_population).png\n                    \n                  . Accessed 01 July 2019."},{"key":"703_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","volume":"13","author":"RL Maher","year":"2014","unstructured":"Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57\u201365.","journal-title":"Expert Opin Drug Saf"},{"key":"703_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37\u201343.","journal-title":"Lancet"},{"key":"703_CR5","first-page":"291","volume":"46","author":"KP Mc Namara","year":"2017","unstructured":"Mc Namara KP, Breken BD, Alzubaidi HAT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia. Age Ageing. 2017;46:291\u20139.","journal-title":"Age Ageing"},{"key":"703_CR6","doi-asserted-by":"publisher","first-page":"e3445","DOI":"10.1136\/bmj.e3445","volume":"344","author":"G Watts","year":"2012","unstructured":"Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012;344:e3445.","journal-title":"BMJ"},{"key":"703_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/ageing\/afv044","volume":"44","author":"A Clegg","year":"2015","unstructured":"Clegg A, Relton C, Young J, et al. Improving recruitment of older people to clinical trials: use of the cohort multiple randomised controlled trial design. Age Ageing. 2015;44:547\u201350.","journal-title":"Age Ageing"},{"key":"703_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/2229-3485.167099","volume":"6","author":"P Shenoy","year":"2015","unstructured":"Shenoy P, Harugeri A. Elderly patients\u2019 participation in clinical trials. Perspect Clin Res. 2015;6:184\u20139.","journal-title":"Perspect Clin Res"},{"key":"703_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-0912-0","volume-title":"Drug therapy for the elderly","author":"M Wehling","year":"2013","unstructured":"Wehling M. Drug therapy for the elderly. Vienna: Springer Publisher; 2013."},{"key":"703_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1532-5415.2011.03252.x","volume":"59","author":"M Wehling","year":"2011","unstructured":"Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc. 2011;59:376\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/archinte.1997.00440350031003","volume":"157","author":"MH Beers","year":"1997","unstructured":"Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157:1531\u20136.","journal-title":"Arch Intern Med"},{"issue":"63","key":"703_CR12","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"2015","author":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society","year":"2015","unstructured":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;2015(63):2227\u201346.","journal-title":"J Am Geriatr Soc"},{"key":"703_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00228-019-02634-z","volume":"75","author":"F Pazan","year":"2019","unstructured":"Pazan F, Kather J, Wehling M. A systematic review and novel classification of listing tools to improve medication in older people. Eur J Clin Pharmacol. 2019;75:619\u201325.","journal-title":"Eur J Clin Pharmacol"},{"key":"703_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.amjopharm.2006.12.008","volume":"4","author":"RL Page","year":"2006","unstructured":"Page RL, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother. 2006;4:297\u2013305.","journal-title":"Am J Geriatr Pharmacother"},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"e009235","DOI":"10.1136\/bmjopen-2015-009235","volume":"5","author":"JA Cooper","year":"2015","unstructured":"Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5:e009235.","journal-title":"BMJ Open"},{"key":"703_CR16","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1055\/s-0028-1091275","volume":"133","author":"M Wehling","year":"2008","unstructured":"Wehling M. Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged FORTA [in German]. Dtsch Med Wochenschr. 2008;133:2289\u201391.","journal-title":"Dtsch Med Wochenschr"},{"key":"703_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40266-013-0146-0","volume":"31","author":"AM Kuhn-Thiel","year":"2014","unstructured":"Kuhn-Thiel AM, Weiss C, Wehling M, FORTA authors\/expert panel members. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131\u201340.","journal-title":"Drugs Aging"},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40266-016-0371-4","volume":"33","author":"F Pazan","year":"2016","unstructured":"Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) list 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging. 2016;33:447\u20139.","journal-title":"Drugs Aging"},{"issue":"5","key":"703_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40266-019-00669-6","volume":"36","author":"F Pazan","year":"2019","unstructured":"Pazan F, Wei\u00df C, Wehling M. The FORTA (Fit fOR The Aged) List 2018: third version of a validated clinical tool for improved drug treatment in older people. Drugs Aging. 2019;36(5):481\u20134. \n                    https:\/\/doi.org\/10.1007\/s40266-019-00669-6\n                    \n                  .","journal-title":"Drugs Aging."},{"key":"703_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/ageing\/afv200","volume":"45","author":"M Wehling","year":"2016","unstructured":"Wehling M, Burkhardt H, Kuhn-Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45:262\u20137.","journal-title":"Age Ageing"},{"key":"703_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40266-017-0514-2","volume":"35","author":"F Pazan","year":"2018","unstructured":"Pazan F, Weiss C, Wehling M. The EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging. 2018;35:61\u201371.","journal-title":"Drugs Aging"},{"key":"703_CR22","unstructured":"FORTA- Fit fOR The Aged. \n                    https:\/\/www.umm.uni-heidelberg.de\/klinische-pharmakologie\/forschung\/forta-projekt\/\n                    \n                  . Accessed 03 May 2019."},{"key":"703_CR23","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288\u201394.","journal-title":"J Clin Epidemiol"},{"key":"703_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"703_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","volume":"44","author":"D O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony D, O\u2019Sullivan D, Byrne S, et al. STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213\u20138.","journal-title":"Age Ageing"},{"key":"703_CR26","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/jgs.14312","volume":"64","author":"MN O\u2019Connor","year":"2016","unstructured":"O\u2019Connor MN, O\u2019Sullivan D, Gallagher PF, et al. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons\u2019 prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64:1558\u201366.","journal-title":"J Am Geriatr Soc"},{"key":"703_CR27","doi-asserted-by":"publisher","first-page":"e0195232","DOI":"10.1371\/journal.pone.0195232","volume":"13","author":"J McIntosh","year":"2018","unstructured":"McIntosh J, Alonso A, MacLure K, Stewart D, Kempen T, et al. A case study of polypharmacy management in nine European countries: implications for change management and implementation. PLoS One. 2018;13:e0195232.","journal-title":"PLoS One"},{"key":"703_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13012-016-0535-y","volume":"12","author":"C J\u00e4ger","year":"2017","unstructured":"J\u00e4ger C, Freund T, Steinh\u00e4user J, Stock C, et al. Impact of a tailored program on the implementation of evidence-based recommendations for multimorbid patients with polypharmacy in primary care practices\u2014results of a cluster-randomized controlled trial. Implement Sci. 2017;12:8.","journal-title":"Implement Sci"},{"key":"703_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12875-018-0795-5","volume":"19","author":"A Rieckert","year":"2018","unstructured":"Rieckert A, Trampisch US, Klaa\u00dfen-Mielke R, Drewelow E, et al. Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19:113.","journal-title":"BMC Fam Pract"},{"key":"703_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/CIA.S94126","volume":"11","author":"K Alagiakrishnan","year":"2016","unstructured":"Alagiakrishnan K, Wilson P, Sadowski CA, Rolfson D, et al. Physicians\u2019 use of computerized clinical decision supports to improve medication management in the elderly \u2013 the Seniors Medication Alert and Review Technology intervention. Clin Interv Aging. 2016;11:73\u201381.","journal-title":"Clin Interv Aging."},{"key":"703_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ageing\/afy086","volume":"47","author":"K Dalton","year":"2018","unstructured":"Dalton K, O\u2019Brien G, O\u2019Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing. 2018;47:670\u20138.","journal-title":"Age Ageing"},{"key":"703_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.11622\/smedj.2014087","volume":"55","author":"CT Chia","year":"2014","unstructured":"Chia CT, Lim WP, Vu CK. Inappropriate use of proton pump inhibitors in a local setting. Singapore Med J. 2014;55:363\u20136.","journal-title":"Singapore Med J"},{"key":"703_CR33","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.","journal-title":"BMJ"},{"key":"703_CR34","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"703_CR35","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/bcp.13055","volume":"82","author":"M Wauters","year":"2016","unstructured":"Wauters M, Elseviers M, Vaes B, Degryse J, et al. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016;82:1382\u201392.","journal-title":"Br J Clin Pharmacol"},{"key":"703_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1932296816651633","volume":"11","author":"K Kostev","year":"2017","unstructured":"Kostev K, Rockel T, Jacob L. Impact of disease management programs on HbA1c values in type 2 diabetes patients in Germany. J Diabetes Sci Technol. 2017;11:117\u201322.","journal-title":"J Diabetes Sci Technol"},{"key":"703_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/pds.3663","volume":"24","author":"F Meier","year":"2015","unstructured":"Meier F, Maas R, Sonst A, et al. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf. 2015;24:176\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"703_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12913-015-0844-x","volume":"15","author":"W Kluchtzner","year":"2015","unstructured":"Kluchtzner W, Grandt D. Influence of hospitalization on prescribing safety across the continuum of care: an exploratory study. BMC Health Serv Res. 2015;15:197.","journal-title":"BMC Health Serv Res"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:19:14Z","timestamp":1597965554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00703-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"22 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was provided for this study and\/or the writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Martin Wehling was employed by AstraZeneca R&D, M\u00f6lndal, as the director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire, and LEO Pharma. Andree Rabenberg, Timo Schulte, and Helmut Hildebrandt have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}